OncoMatch

OncoMatch/Clinical Trials/NCT07189403

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

Is NCT07189403 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DS9051b for advanced or metastatic adrenocortical carcinoma.

Phase 1RecruitingDaiichi SankyoNCT07189403Data as of May 2026

Treatment: DS9051bThis FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Prostate Cancer

Disease stage

Required: Stage IV

advanced or metastatic

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: androgen receptor pathway inhibitor (abiraterone, enzalutamide, darolutamide, apalutamide) — cspc or crpc

Must have received: chemotherapy

Lab requirements

Blood counts

adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to C1D1 as defined below. Organ and bone marrow function criteria must also be met when laboratory tests are repeated within 3 days of initiation of trial intervention as appropriate.

Kidney function

adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to C1D1 as defined below. Organ and bone marrow function criteria must also be met when laboratory tests are repeated within 3 days of initiation of trial intervention as appropriate.

Liver function

adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to C1D1 as defined below. Organ and bone marrow function criteria must also be met when laboratory tests are repeated within 3 days of initiation of trial intervention as appropriate.

Has adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to C1D1 as defined below. Organ and bone marrow function criteria must also be met when laboratory tests are repeated within 3 days of initiation of trial intervention as appropriate.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Florida Cancer Specialists · Sarasota, Florida
  • Columbia University · New York, New York
  • Brown University · Providence, Rhode Island

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify